Cathie Wood Sells Meta Stock to Fund a Massive Bet on Healthcare AI
St. Petersburg, Thursday, 26 March 2026.
This week, Cathie Wood’s ARK Invest liquidated shares across 18 companies, notably Meta, to aggressively concentrate its capital into a single emerging healthcare artificial intelligence firm: Tempus AI.
A Strategic Pivot Away from Mature Tech
On March 25, 2026, ARK Invest executed a significant portfolio rebalancing, notably reducing its exposure to Meta Platforms (META) and Roku (ROKU) [1][3]. The innovation-focused fund divested 3,578 Meta shares, securing approximately $2.1 million, which implies an average execution price of roughly $586.92 per share [1]. This decision aligns with recent fundamental challenges for the social media giant, which is currently navigating a lawsuit verdict finding the company negligent regarding harm to minors on its platform, alongside newly announced workforce reductions [1]. Despite the sale, ARK retains roughly 105,000 Meta shares in its ARK Innovation ETF (ARKK), valued at approximately $63 million, which constitutes about 1% of the fund’s total assets [1]. Concurrently, ARK liquidated 95,090 Roku shares, pulling in an additional $9.1 million [1].
Doubling Down on Healthcare AI
The primary beneficiary of this massive capital rotation was Tempus AI (TEM.US) [2]. In a stark contrast to the widespread selling, Tempus AI emerged as the sole equity targeted for increased buying activity by ARK on March 25 [2]. The fund acquired 84,939 shares of the healthcare artificial intelligence firm for roughly $4.1 million, executing at an estimated average of $48.27 per share [1]. This aggressive accumulation capitalized on a recent dip in the stock’s value, as Tempus AI had experienced a 4.2% daily decline on March 24 and retreated 21% year-to-date in 2026 [1]. Following these transactions, Tempus AI now stands as the third-largest allocation within the ARK Innovation ETF, representing 5% of the fund’s total assets with approximately 6.3 million shares valued at over $294 million [1].
Capitalizing on Crypto and Biotech Volatility
Beyond the Tempus AI consolidation, ARK’s trading desk has been actively exploiting market volatility across other sectors. Earlier in the week, on March 24, 2026, ARK’s ETFs poured $16.3 million into Circle Internet (CRCL), acquiring 161,513 shares to capitalize on a steep 20.1% dip in the stock’s price [4]. Conversely, the fund took profits in the biotech space, selling 190,100 shares of Twist Bioscience (TWST) for $9.03 million after the stock experienced a 6.7% surge [4]. These tactical moves highlight a clear strategy: selling into strength and buying into weakness.